Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969068 | 0.83 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL14367955 | 0.81 | ALDH1A1 (0.52) | SLC6A4SLC6A2SLC6A3ALDH1A1PKM | |
| SCHEMBL24229608 | 0.79 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6450366 | 0.79 | CYP3A4 (0.55) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL31472982 | 0.77 | ALDH1A1 (0.47) | SLC6A4SLC6A2SLC6A3ALDH1A1PKM | |
| SCHEMBL4590973 | 0.77 | ALDH1A1 (0.47) | SLC6A4SLC6A2SLC6A3ALDH1A1PKM | |
| SCHEMBL28205058 | 0.77 | CYP3A4 (0.50) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL8533455 | 0.77 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL8535028 | 0.77 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4236353 | 0.76 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015004481-A1 | IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS) | ASTEX THERAPEUTICS LIMITED (GB) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015004481-A1 | IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS) | ASTEX THERAPEUTICS LIMITED (GB) | 2015-01-15 | — | — | WO | disclosed |
| EP-1751136-B1 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-1751136-B1 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2014-07-02 | — | — | EP | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7880000-B2 | N-(5-(1,1- dimethylethyl)-3- isoxazolyl)-4-methyl-3- ((3-(4-pyrimidinyl)-2- pyridinyl)amino)benzamide, used for treating breast cancer or rheumatoid arthritis | AMGEN INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880000-B2 | N-(5-(1,1- dimethylethyl)-3- isoxazolyl)-4-methyl-3- ((3-(4-pyrimidinyl)-2- pyridinyl)amino)benzamide, used for treating breast cancer or rheumatoid arthritis | AMGEN INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880000-B2 | N-(5-(1,1- dimethylethyl)-3- isoxazolyl)-4-methyl-3- ((3-(4-pyrimidinyl)-2- pyridinyl)amino)benzamide, used for treating breast cancer or rheumatoid arthritis | AMGEN INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20060009453-A1 | Protein kinase modulators and method of use | AMGEN INC. | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009453-A1 | Protein kinase modulators and method of use | PHKG1, PRKCH, BMP2K | SLC6A4 4798/4885SLC6A2 4883/4885SLC6A3 4844/4885 |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | GRK4, MAP4K5, GRK5 | SLC6A4 4622/4885SLC6A2 4863/4885SLC6A3 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.